Results 61 to 70 of about 27,163 (253)

A experiência da vida real com complicações cardiovasculares na primeira dose de fingolimode [PDF]

, 2014
Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion.
Arruda, Christian Cardoso, Arruda, Walter Oleschko, Brooks, Joseph Bruno Bidin, Damasceno, Alfredo, Damasceno, Carlos Augusto de Albuquerque, Finkelsztejn, Alessandro, Finkelsztejn, Juliana, Fragoso, Yara Dadalti, Gama, Paulo Diniz da, Giacomo, Maria Cristina Brandão, Gomes, Sidney, Goncalves, Marcus Vinicius Magno, Matta, Andre Palma da Cunha, Morais, Marilia Manprim de, Oliveira, Enedina Maria Lobato de, Ribeiro, Yuna, Sato, Henry Koiti, Tauil, Carlos Bernardo   +17 more
core   +4 more sources

Discovery of an Adaptive Neuroimmune Response Driving Itch and Fast Tick Removal with Implications for Preventing Pathogen Transmission

Advanced Science, EarlyView.
Doehl et al. discovered an adaptive neuroimmune mechanism that induces itch in tick‐exposed guinea pigs, enabling rapid tick removal. This itch‐induced tick removal (IITR) is mediated by an adaptive cellular immune response and is independent of IgG, IgE, or TRPV1.
Johannes S. P. Doehl, Tiago D. Serafim, Serena Doh, Charles S. Grugan, Eva Iniguez, Luana Rogerio, Ronja Frigard, Ranadhir Dey, Pedro Cecilio, Xinglong Gu, Pang‐Yen Tseng, Aline da Silva Moreira, Mahnaz Minai, James Oristian, Hans Ackerman, Steven Brooks, Caroline Percopo, Siu‐Ping Ng, Derron A. Alves, Lucas Tirloni, Jennifer M. Anderson, Adriana Marques, Fabiano Oliveira, Shaden Kamhawi, Daniel E. Sonenshine, José M. C. Ribeiro, Mark Hoon, Jesus G. Valenzuela   +27 more
wiley   +1 more source

Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod

Drug Design, Development and Therapy, 2014
Jorge Correale,1 Erwin Chiquete,2 Snezana Milojevic,3 Nadina Frider,3 Imre Bajusz31Raúl Carrea Institute for Neurological Research, Foundation for the Fight against Infant Neurological Illnesses, Buenos Aires, Argentina; 2Department of Neurology ...
Correale J, Chiquete E, Milojevic S, Frider N, Bajusz I   +4 more
doaj  

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis

Drugs in R&D, 2020
Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases.
Pablo Bascuñana, Luisa Möhle, Mirjam Brackhan, Jens Pahnke   +3 more
doaj   +1 more source

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

Journal of Neuroinflammation, 2022
Background The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine.
Celia Camacho-Toledano, Isabel Machín-Díaz, Leticia Calahorra, María Cabañas-Cotillas, David Otaegui, Tamara Castillo-Triviño, Luisa María Villar, Lucienne Costa-Frossard, Manuel Comabella, Luciana Midaglia, José Manuel García-Domínguez, Jennifer García-Arocha, María Cristina Ortega, Diego Clemente   +13 more
doaj   +1 more source

AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition and Lipid Droplets Accumulation

Advanced Science, EarlyView.
Microglial AXL drives white matter repair after stroke by orchestrating the cleanup of myelin debris. Mechanistically, AXL signals through EGR1 to boost Smpd1 transcription, regulating sphingolipid metabolism and preventing lipid droplet toxicity. Restoring the pathway with ASM therapy mitigates damage, positioning AXL as a key node for therapeutic ...
Junqiu Jia, Yonghui Gan, Jia Li, Lilin Li, Hailan Meng, Min Sun, Lei Ye, Rui Mao, Xiang Cao, Shengnan Xia, Xinyu Bao, Renyuan Liu, Meijuan Zhang, Yun Xu   +13 more
wiley   +1 more source

Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

, 2013
Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS).
Friede, Tim, Nicholas, Richard, Röver, Christian, Schneider, Simon, Steinvorth, Simon M., Straube, Sebastian   +5 more
core   +1 more source

Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage [PDF]

, 2021
Andrea Díaz Díaz, Jennifer A. Shearer, Kyle Malone, Christian Waeber   +3 more
openalex   +1 more source

F13A1‐Mediated Macrophage Activation Promotes MASH Progression via the PKM2/HIF1A Pathway

Advanced Science, EarlyView.
In fatty liver disease, hepatocytes exposed to palmitate release S1P, which activates calcium signaling in macrophages. Elevated calcium enhances the activity of F13A1, driving PKM2 dimerization. The PKM2 dimers cause Warburg effect, translocate to the nucleus, cooperate with HIF1A, and upregulate IL1B expression, ultimately promoting classical ...
Qianrang Lu, Meiching Ong, Xuewen Yi, Muqiong Xing, Xinyao Tian, Ke Zhang, Ling Lu, Hao Wang, Xiaohan Lin, Jun Fang, Aibo Mu, Jiaying Cao, Jingyu Jiang, Feng Gao, Hongjun Li, Baohong Wang, Qi Ling   +16 more
wiley   +1 more source

Effect of fingolimod on platelet count among multiple sclerosis patients

International Journal of Preventive Medicine, 2015
Background: While many studies have previously focused on fingolimod′s effect on immune cells, the effect it has on circulating and local central nervous system platelets (Plts) has not yet been investigated.
Mehrdad Farrokhi, Ali Amani Beni, Masoud Etemadifar, Ali Rezaei, Leah Rivard, Aryan Rafiee Zadeh, Nahid Sedaghat, Milad Ghadimi   +7 more
doaj   +1 more source